Uniquity Bio Advances Esophageal Drug Toward Phase 3 Trial
MALVERN, PA — Uniquity Bio plans to begin a pivotal Phase 3 trial of its experimental esophageal disease treatment in early 2027 after reporting statistically significant improvements in swallowing symptoms …
Uniquity Bio Advances Esophageal Drug Toward Phase 3 Trial Read More